On Saturday, the seventh-seeded Indian duo was defeated by South Korea's Kim Won-ho and Seo Seung-Jae 10-21, 15-21 in a rather one-sided match within 40 minutes, bringing an end to the Indian ...

Here are all the updates from January 11, 2025. Badminton: A big one as Satwiksairaj Rankireddy and Chirag look to reach the final of the season-opening Malaysia Open Super 1000. Their men's ...

Indian badminton stars Satwiksairaj Rankireddy and Chirag Shetty continued their stellar run on the international stage by reaching the men’s doubles semifinals of the prestigious Malaysia Open Super ...

Royalty Pharma (RPRX) announced two major steps to enhance shareholder value. First, the Board of Directors has agreed to acquire its external manager, RP Management. This transaction to simplify ...

Top male singles player H.S Prannoy, doubles specialists Satwiksairaj Rankireddy/Chirag Shetty, women’s singles star Malvika Bansod, mixed doubles pair Dhruv Kapila/Tanisha Crasto and Sathish ...

India has been traditionally quite strong in the pharma sector, with a low cost of manufacturing (30%–35% lower than in the US and Europe), cost-efficient R&D (about 87% less than in developed markets ...

(Image Credits: Pixabay) Amid the growing burden of non-communicable diseases and ageing population, the pharmaceutical sector has thrived tremendously over the recent years. Industry leaders ...

Overall, biopharma layoffs rose ever so slightly in 2024 compared to the year before, though the number of layoff rounds across Big Pharma skyrocketed by 281%. In 2024, Fierce Biotech reported 192 ...

Novo Nordisk, for its part, is expected to jump from 10th place to sixth this year, according to Evaluate Pharma’s consensus forecasts. Nevertheless, it’s Roche that’s been tipped to stand ...

Big Pharma will hunt for more acquisitions in 2025 as industry giants face patent expiration for some of their best-selling drugs, according to a top M&A banker. Merck's cancer drug Keytruda ...

Veeda Group has unveiled a new logo and brand identity—Veeda Lifesciences—reflecting ... with reputable sponsors, including leading global pharma companies.

A Reuters analysis of prices for new drugs found that pharmaceutical companies launched new U.S. drugs in 2023 at prices 35% higher than in 2022. The over 250 drug hikes represent an increase from ...